  Diseases and Conditions Surgical Procedures Lab Tests Symptoms Nutrition Special Topics  Anatomy Explorer BMI Calculator Health IQ Ready When You Are Resources Newsletter Register Symptom Manager  Allergies & Asthma Arthritis Back Pain Bone, Joint & Muscle Cancer Diabetes Eye Headache Heart HIV/AIDS The New You Parenting Womens Health Alternative Medicine Before Your Visit More... Register
Copyright 1998-2005. |
| FDA Approves Gloucester Pharmaceuticals' ISTODAX(R) For Patients With Cutaneous T-cell Lymphoma Gloucester Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) approved ISTODAX® (romidepsin) for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. The approval of ISTODAX was based on objective disease response defined as the proportion of patients with confirmed complete response or partial response. |